Underwood Brynne, Zhao Qiuhong, Walker Alison R, Mims Alice S, Vasu Sumithira, Long Meixiao, Z Haque Tamanna, Blaser Bradley W, Grieselhuber Nicole R, Wall Sarah A, Behbehani Gregory K, Blachly James S, Larkin Karilyn, Byrd John C, Garzon Ramiro, Wang Tzu-Fei, Bhatnagar Bhavana
Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Int J Hematol Oncol. 2020 Sep 4;9(3):IJH28. doi: 10.2217/ijh-2020-0009.
There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.
MATERIALS & METHODS: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.
18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.
These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.
关于接受聚乙二醇天冬酰胺酶治疗的青少年及青年急性淋巴细胞白血病（AYA-ALL）患者出现症状性静脉血栓栓塞（VTE）的发生率，相关数据有限。
对4家机构中接受聚乙二醇天冬酰胺酶治疗的44例AYA-ALL患者进行单机构回顾性分析。评估VTE发生率及潜在风险因素。
18例患者（41%）在接受聚乙二醇天冬酰胺酶治疗后出现症状性VTE。初始剂量后30天内累积发生率为25%（95%CI：13-38%）。校正性别因素后，血栓形成个人史与VTE风险增加在统计学上显著相关，风险比为2.73（95%CI：1.40-5.33，P=0.003）。
这些数据表明，AYA-ALL患者接受聚乙二醇天冬酰胺酶治疗后VTE发生率较高。
